Coronary disease & ACS

Randomized Feasibility Trial of Routine Versus Selective Transesophageal Echocardiography During Isolated Coronary Artery Bypass Grafting

JACC AdvPublished pragmatic, randomized feasibility trial

Authors' conclusion

In this pragmatic randomized feasibility trial, both TEE strategies were successfully implemented with high protocol adherence and preserved clinician and patient equipoise, supporting a multicenter randomized trial evaluating routine vs selective TEE during isolated CABG.

Study context

Population
Adults undergoing isolated coronary artery bypass grafting (CABG) for whom both strategies were clinically acceptablerandomized following induction of anesthesia, 274 screened, 72 eligible, 46 (64%) consented
Participants
40 adults
Comparison
Transesophageal echocardiography (TEE)-by-default vs TEE-on-demand
  • TEE-by-defaultn = 20
  • TEE-on-demandn = 20
Methodological details2 tertiary-care hospitals within a single health system
  • 2 tertiary-care hospitals within a single health system

Primary result

As reported in the abstract

Primary feasibility outcomes: enrollment, successful randomization, and protocol adherence
Screened
274
Eligible
72
Consented (of eligible)
46 (64%)
Randomized
40 (56% of eligible; 87% of consented)
Protocol adherence
39/40; 98%
Allocation error
1

Further findings

Clinically triggered TEE in the TEE-on-demand arm
15% · 3 of 20 of 20

Safety

Deaths · within 90 days

No deaths occurred

Serious adverse events adjudicated as related to TEE exposure

Serious adverse events related to TEE exposure
Three
Esophageal complications
2
Conversion to combined CABG and mitral valve replacement
1

Original publication

Randomized Feasibility Trial of Routine Versus Selective Transesophageal Echocardiography During Isolated Coronary Artery Bypass Grafting. JACC Adv. Published 20 July 2026. doi:10.1016/j.jacadv.2026.103030

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.